Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A and C and haemophilus type b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial Center for Disease Control and Prevention
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The AC meningococcal groups A and C and Haemophilus b conjugate vaccine is a trivalent combination vaccine developed by Beijing Zhifei Lüzhu Biopharmaceutical. It is designed to provide simultaneous protection against invasive diseases caused by *Neisseria meningitidis* serogroups A and C and *Haemophilus influenzae* type b (Hib), including meningitis, pneumonia, and sepsis. The vaccine utilizes capsular polysaccharides from each pathogen, which are individually conjugated to a carrier protein (typically tetanus toxoid) to convert the T-cell independent polysaccharide antigens into T-cell dependent antigens, thereby inducing a robust immune response and immunological memory in infants and young children. While a non-adjuvanted version (marketed as Xifibe) is approved in China, clinical trials (such as CTR20191651) have evaluated adjuvanted formulations to potentially enhance immunogenicity in the primary series for infants.
- Brand names
- Xifibe喜菲贝
- Other names
- AC-Hib conjugate vaccineGroup A and Group C Meningococcal and Haemophilus b Conjugate VaccineAC meningococcal groups A and C and Haemophilus b conjugate vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A and C and haemophilus type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A and C and haemophilus type b conjugate vaccine.